CUMYL-CBMINACA

CUMYL-CBMINACA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide;
PubChem CID	155884799;
ChemSpider	90606548;
UNII	3DAF3CP9N5;
CompTox Dashboard (EPA)	DTXSID101336534 ;
Chemical and physical data
Formula	C22H25N3O
Molar mass	347.462 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(NC(=O)c3nn(CC1CCC1)c2ccccc23)c4ccccc4;
	InChI InChI=1S/C22H25N3O/c1-22(2,17-11-4-3-5-12-17)23-21(26)20-18-13-6-7-14-19(18)25(24-20)15-16-9-8-10-16/h3-7,11-14,16H,8-10,15H2,1-2H3,(H,23,26); Key:CFMZQSDQCNKGII-UHFFFAOYSA-N;

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,^[1] first being identified in Germany in February 2020.^[2] It is illegal in Finland.^[3]